CAM
OVID icon

Cormorant Asset Management’s Ovid Therapeutics OVID Stock Holding History

Cormorant Asset Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-223,972
Closed -$2.21M – 57
2017
Q4 		$2.21M Hold
223,972
– – 0.23% 48
2017
Q3 		$1.92M Hold
223,972
– – 0.34% 45
2017
Q2 		$2.35M Buy
+223,972
New +$2.92M 0.39% 53

Other funds holding OVID

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Cormorant Asset Management's OVID Position: Q1 2018 in Review

Cormorant Asset Management sold out of Ovid Therapeutics (OVID) in Q1 2018, closing a stake of 223,972 shares — an estimated $2.21M sold.

Cormorant Asset Management first reported a position in OVID in Q2 2017 and held it in 3 quarters. The position peaked at $2.35M in Q2 2017. 48 funds tracked by Wall St. Rank hold OVID as of Q1 2018.

  • Cormorant Asset Management reported no remaining Ovid Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Cormorant Asset Management sold 223,972 Ovid Therapeutics shares in Q1 2018, an estimated $2.21M.
  • Cormorant Asset Management first reported a position in Ovid Therapeutics in Q2 2017 and held it in 3 quarters.
  • Cormorant Asset Management's Ovid Therapeutics position peaked at $2.35M in Q2 2017.
  • 48 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2018.

Based on Cormorant Asset Management's 13F filing for Q1 2018, filed 15 May 2018.